Work

Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.8026

Authors: Jonathan Wade Goldman, Leena Gandhi, Amita Patnaik, Lee S. Rosen, John Frederick Hilton, Kyriakos P. Papadopoulos, Sara M. Tolaney, Muralidhar Beeram, Drew Warren Rasco, Scott P. Myrand, Richard P Beckmann, Palaniappan Kulanthaivel, Martin Frenzel, Damien Cronier, Edward M. Chan, Keith Flaherty, Patrick Y. Wen, Anthony W. Tolcher, Geoffrey Shapiro

Institutions: University of California, Los Angeles, Dana-Farber Cancer Institute, South Texas Accelerated Research Therapeutics, Eli Lilly (United States), Harvard University, Massachusetts General Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2598073686

Cites:

Cited by: 27

Related to: 10